Alkermes Announces Notice of Allowance of USPTO Application for Aripiprazole Lauroxil
plc (NASDAQ: ALKS) today announced that the United States Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
Patent Application 12/823,007, titled “Heterocyclic Compounds for the
Treatment of Neurological and Psychological Disorders.” The allowed
claims will cover a class of compounds that includes aripiprazole
lauroxil, a proprietary Alkermes molecule formerly referred to as ALKS
9070, which is in development for the treatment of schizophrenia.
Aripiprazole lauroxil is designed to provide patients with once-monthly
dosing of a medication that, once in the body, converts into
aripiprazole, a molecule that is commercially available under the name
ABILIFY® for the treatment of a number of central nervous
system (CNS) disorders.